Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Hartley

Showing results (1-10 of 164) with videos related to

Pageof 17
Sort By:
Expert Opinion on Biological Therapy|June 17, 2020
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapyJohn A Hartley
Expert Opinion on Investigational Drugs|April 5, 2011
The development of pyrrolobenzodiazepines as antitumour agentsJohn A Hartley
Current Opinion in Pharmacology|April 17, 2012
Small molecule drugs - optimizing DNA damaging agent-based therapeuticsJohn A Hartley, Daniel Hochhauser
Frontiers in Oncology|July 3, 2025
A spotlight on the MSc Cancer at UCL, 15 years onSarah Koushyar, John A Hartley
British Journal of Haematology|May 31, 2017
The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancerMichael J Flynn, John A Hartley
Seminars in Hematology|May 3, 2011
Mechanism of action: the unique pattern of bendamustine-induced cytotoxicityLorenzo M Leoni, John A Hartley
Current Topics in Medicinal Chemistry|April 14, 2015
Therapeutic Agents Based on DNA Sequence Specific BindingLuke Pett, John A Hartley, Konstantinos Kiakos
Cancer Research|January 27, 2011
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2014
Importance of EGFR/ERCC1 interaction following radiation-induced DNA damageGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Methods in Molecular Biology (Clifton, N.J.)|December 10, 2009
Measurement of DNA interstrand crosslinking in naked DNA using gel-based methodsKonstantinos Kiakos, Janet M Hartley, John A Hartley
Pageof 17

Showing results (1-10 of 164) with videos related to

Sort By:
Pageof 17
Expert Opinion on Biological Therapy|June 17, 2020
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapyJohn A Hartley
Expert Opinion on Investigational Drugs|April 5, 2011
The development of pyrrolobenzodiazepines as antitumour agentsJohn A Hartley
Current Opinion in Pharmacology|April 17, 2012
Small molecule drugs - optimizing DNA damaging agent-based therapeuticsJohn A Hartley, Daniel Hochhauser
Frontiers in Oncology|July 3, 2025
A spotlight on the MSc Cancer at UCL, 15 years onSarah Koushyar, John A Hartley
British Journal of Haematology|May 31, 2017
The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancerMichael J Flynn, John A Hartley
Seminars in Hematology|May 3, 2011
Mechanism of action: the unique pattern of bendamustine-induced cytotoxicityLorenzo M Leoni, John A Hartley
Current Topics in Medicinal Chemistry|April 14, 2015
Therapeutic Agents Based on DNA Sequence Specific BindingLuke Pett, John A Hartley, Konstantinos Kiakos
Cancer Research|January 27, 2011
EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatmentGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2014
Importance of EGFR/ERCC1 interaction following radiation-induced DNA damageGianmaria Liccardi, John A Hartley, Daniel Hochhauser
Methods in Molecular Biology (Clifton, N.J.)|December 10, 2009
Measurement of DNA interstrand crosslinking in naked DNA using gel-based methodsKonstantinos Kiakos, Janet M Hartley, John A Hartley
Pageof 17